

REFERENCES

1. Daly JM, D.J., *Principles of surgical oncology*, in *Medical Oncology*, S.P. Calabrese P, Rosenberg SA, , Editor. 1985, Macmillan: Toronto, Canada. p. 261.
2. KR, F., *Surgery in the patient with cancer*, in *Perioperative Medicine: Medical Care of the Surgical Patient*, B.F. Goldmann DR, Guarnieri DM, Editor. 1994, McGraw-Hill: New York, NY. p. 283-293.
3. Sahai, S. and H. Ismail, *Perioperative Implications of Neoadjuvant Therapies and Optimization Strategies for Cancer Surgery*. *Current Anesthesiology Reports*, 2015. **5**(3): p. 305-317.
4. Levine, G.N., et al., *2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines*. An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery, 2016.
5. Fleisher, L.A., et al., *2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery*. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, 2014. **64**(22): p. e77-e137.
6. Bdair, F.M., et al., *Gemcitabine and acute myocardial infarction--a case report*. *Angiology*, 2006. **57**(3): p. 367-71.
7. Khakoo, A.Y. and E.T. Yeh, *Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy*. *Nat Clin Pract Oncol*, 2008. **5**(11): p. 655-67.
8. Gharib, M.I. and A.K. Burnett, *Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis*. *Eur J Heart Fail*, 2002. **4**(3): p. 235-42.
9. Chu, T.F., et al., *Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib*. *Lancet*, 2007. **370**(9604): p. 2011-9.
10. Ewer MS, B.R., *Cardiac complications*, in *Cancer Medicine*, K.D. Bast RC, Pollock RE, Editor. 2000, B.C. Decker, Inc: London. p. 2324-2339.
11. Zambetti, M., et al., *Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation*. *J Clin Oncol*, 2001. **19**(1): p. 37-43.
12. Ando, M., et al., *Cardiac conduction abnormalities in patients with breast cancer undergoing high-dose chemotherapy and stem cell transplantation*. *Bone Marrow Transplant*, 2000. **25**(2): p. 185-9.
13. Kaur, A., et al., *Thalidomide-induced sinus bradycardia*. *Ann Pharmacother*, 2003. **37**(7-8): p. 1040-3.
14. Wilke, A., et al., *Elevation of the pacing threshold: a side effect in a patient with pacemaker undergoing therapy with doxorubicin and vincristine*. *Oncology*, 1999. **56**(2): p. 110-1.
15. Adams, M.J., et al., *Radiation-associated cardiovascular disease*. *Crit Rev.Oncol.Hematol.*, 2003. **45**(1): p. 55-75.
16. Basavaraju, S.R. and C.E. Easterly, *Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications*. *Med.Phys.*, 2002. **29**(10): p. 2391-2403.

17. Kelly, K., et al., *Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors*. Target Oncol, 2009. **4**(2): p. 99-105.
18. Lombardi, G., et al., *Diagnosis and Treatment of Malignant Pleural Effusion: A Systematic Literature Review and New Approaches*. Am J Clin Oncol, 2009.
19. Tashiro, M., et al., *Lung fibrosis 10 years after cessation of bleomycin therapy*. Tohoku J Exp Med, 2008. **216**(1): p. 77-80.
20. Einhorn, L., et al., *Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer*. Cancer, 1976. **37**(5): p. 2414-6.
21. Carver, J.R., et al., *American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects*. Journal of Clinical Oncology, 2007. **25**(25): p. 3991-4008.
22. Sekine, Y., et al., *Perioperative rehabilitation and physiotherapy for lung cancer patients with chronic obstructive pulmonary disease*. Jpn.J.Thorac.Cardiovasc.Surg., 2005. **53**(5): p. 237-243.
23. Samama, C.M., et al., *Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003*. Minerva Anesthesiol, 2006. **72**(6): p. 447-52.
24. Devon, K.M. and R.S. McLeod, *Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery*. Cochrane Database Syst Rev, 2009(1): p. Cd007148.
25. Carson, J.L., et al., *Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion*. Cochrane Database Syst Rev, 2016. **10**: p. Cd002042.
26. Roubinian, N. and J.L. Carson, *Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy*. Hematol Oncol Clin North Am, 2016. **30**(3): p. 529-40.
27. Bauhofer, A., et al., *Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: A randomized, controlled trial*. Surgery, 2007. **141**(4): p. 501-10.
28. Schaefer, H., et al., *Perioperative granulocyte colony-stimulating factor does not prevent severe infections in patients undergoing esophagectomy for esophageal cancer: a randomized placebo-controlled clinical trial*. Ann Surg, 2004. **240**(1): p. 68-75.
29. Lyman, G.H. and M. Shayne, *Granulocyte colony-stimulating factors: finding the right indication*. Curr Opin Oncol, 2007. **19**(4): p. 299-307.
30. Massey, E., et al., *Granulocyte transfusions for preventing infections in patients with neutropenia or neutrophil dysfunction*. Cochrane Database Syst Rev, 2009(1): p. CD005341.
31. Bratzler, D.W. and D.R. Hunt, *The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery*. Clin Infect Dis, 2006. **43**(3): p. 322-30.
32. Groeben, H., A. Heyll, and J. Peters, *[Pathophysiologic and anesthesiologic characteristics of patients with leukemia]*. Anaesthesist, 1992. **41**(8): p. 438-47.
33. Lyman, G.H., et al., *Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014*. Journal of Clinical Oncology, 2015. **33**(6): p. 654-656.
34. (NCCN), N.C.C.N. *NCCN Clinical Practice Guidelines in Oncology. Cancer Associated Venous Thromboembolic Disease Version 1.2017* 2017 [cited 2017 10/28/2017]; Available from: http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf.
35. Chun, Y.S., et al., *Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases*. Lancet Oncol, 2009. **10**(3): p. 278-86.
36. Stohr, W., et al., *Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system*. Pediatr Blood Cancer, 2007. **48**(2): p. 140-7.
37. Kintzel, P.E., *Anticancer drug-induced kidney disorders*. Drug Saf, 2001. **24**(1): p. 19-38.

38. Lajer, H., et al., *Magnesium and potassium homeostasis during cisplatin treatment*. *Cancer Chemother Pharmacol*, 2005. **55**(3): p. 231-6.
39. Lajer, H. and G. Daugaard, *Cisplatin and hypomagnesemia*. *Cancer Treat Rev*, 1999. **25**(1): p. 47-58.
40. Jones, D.P., et al., *Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group*. *Pediatr Blood Cancer*, 2008. **51**(6): p. 724-31.
41. Kearon, C., et al., *Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report*. *Chest*, 2016. **149**(2): p. 315-352.
42. Lyman, G.H., et al., *Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update*. *J Oncol Pract*, 2015. **11**(3): p. e442-4.
43. Ambiru, S., et al., *Poor postoperative blood glucose control increases surgical site infections after surgery for hepato-biliary-pancreatic cancer: a prospective study in a high-volume institute in Japan*. *J Hosp Infect*, 2008. **68**(3): p. 230-3.
44. Nieto, A., et al., *Determinants of wound infections after surgery for breast cancer*. *Zentralbl Gynakol*, 2002. **124**(8-9): p. 429-33.
45. Shiono, S., et al., *Risk factors of postoperative respiratory infections in lung cancer surgery*. *J Thorac Oncol*, 2007. **2**(1): p. 34-8.
46. Uchiyama, K., et al., *Prevention of postoperative infections by administration of antimicrobial agents immediately before surgery for patients with gastrointestinal cancers*. *Hepatogastroenterology*, 2007. **54**(77): p. 1487-93.
47. Okabayashi, T., et al., *Risk factors and predictors for surgical site infection after hepatic resection*. *J Hosp Infect*, 2009. **73**(1): p. 47-53.
48. Valentini, V., et al., *Diabetes as main risk factor in head and neck reconstructive surgery with free flaps*. *J Craniofac Surg*, 2008. **19**(4): p. 1080-4.
49. Warren, A.G., et al., *Lymphedema: a comprehensive review*. *Ann Plast Surg*, 2007. **59**(4): p. 464-72.
50. Sahai, S.K., A. Zalpour, and M.A. Rozner, *Preoperative evaluation of the oncology patient*. *Anesthesiol Clin*, 2009. **27**(4): p. 805-22.
51. Casey, A.L. and T.S. Elliott, *Progress in the prevention of surgical site infection*. *Curr Opin Infect Dis*, 2009. **22**(4): p. 370-5.
52. Deshaies, I., et al., *Antiangiogenic agents and late anastomotic complications*. *J Surg Oncol*, 2009.
53. Shane, E. *Treatment of hypercalcemia*. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <http://www.uptodate.com>. Accessed on February 15, 2018.
54. Brahmer, J.R., et al and in collaboration with the National Comprehensive Cancer Network. *Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline*. *J Clin Oncol*, 2018. **36**(17): p. 1714-1768.